Endocrine Reviews 22 (2): 226-239
Copyright © 2001 by The Endocrine Society
Y Chromosome Microdeletions and Alterations of Spermatogenesis1
Carlo Foresta,
Enrico Moro and
Alberto Ferlin
University of Padova, Department of Medical and Surgical Sciences,
Clinica Medica 3, 35128 Padova, Italy
 |
Abstract
|
|---|
Three different spermatogenesis loci have been mapped on the Y
chromosome and named "azoospermia factors" (AZFa,
b, and c). Deletions in these regions
remove one or more of the candidate genes (DAZ,
RBMY, USP9Y, and DBY) and
cause severe testiculopathy leading to male infertility. We have
reviewed the literature and the most recent advances in Y chromosome
mapping, focusing our attention on the correlation between Y chromosome
microdeletions and alterations of spermatogenesis. More than 4,800
infertile patients were screened for Y microdeletions and published.
Such deletions determine azoospermia more frequently than severe
oligozoospermia and involve especially the AZFc region
including the DAZ gene family. Overall, the prevalence
of Y chromosome microdeletions is 4% in oligozoospermic patients, 14%
in idiopathic severely oligozoospermic men, 11% in azoospermic men,
and 18% in idiopathic azoospermic subjects. Patient selection criteria
appear to substantially influence the prevalence of microdeletions. No
clear correlation exists between the size and localization of the
deletions and the testicular phenotype. However, it is clear that
larger deletions are associated with the most severe testicular damage.
Patients with Y chromosome deletions frequently have sperm either in
the ejaculate or within the testis and are therefore suitable
candidates for assisted reproduction techniques. This possibility
raises a number of medical and ethical concerns, since the use of
spermatozoa carrying Y chromosome deletions may produce pregnancies,
but in such cases the genetic anomaly will invariably be passed on to
male offspring.
I. Introduction
II. Structure and Gene Content of the Y Chromosome
III. The Azoospermia Factors
IV. AZFb Region and Candidate Genes
V. AZFc Region and Candidate Genes
VI. AZFa Region and Candidate Genes
VII. Y Chromosome Microdeletions in Infertile Men
A. Methods of detection
B. Selection of patients, phenotype-genotype relation, and origin of
deletions
C. The concern of assisted reproduction techniques
VIII. Conclusions
 |
I. Introduction
|
|---|
THE Y chromosome is not essential for life and until
recently most regions of it were assumed to be functionally inert. Sex
determination (controlled by the SRY gene) (1) has long been
viewed as the sole function related to the Y chromosome (2), but this
theory changed in recent years when another important function (the
control of spermatogenesis) (3) was discovered and many genes were
mapped to the Y chromosome.
Spermatogenesis is a long and complex process requiring about 70 days
and involving an elaborate succession of distinct cell types (4, 5)
generated by mitotic and meiotic divisions. In the initial stages,
spermatogonia divide via mitoses, giving rise to primary spermatocytes,
which in turn undergo the first meiotic division leading to
secondary spermatocytes. Through the second meiosis these cells produce
haploid cells (round spermatids), which elongate during the
spermiogenesis process (elongated spermatids) and finally differentiate
into mature spermatozoa, by condensation of the chromatin, substitution
of histones with protamines, and formation of the acrosome and the
other sperm components. However, our knowledge of the mechanisms
regulating spermatogenesis is still poor, and only recently has
research focused on the identification of genes specifically involved
in its regulation.
Nevertheless, infertility is a major health problem affecting 1015%
of couples seeking to have children, and a male factor can be
identified in about half of these cases (6). A significant proportion
of infertile males are affected either by oligozoospermia (reduced
sperm production) or azoospermia (lack of any sperm in the ejaculate).
Such alterations in sperm production may be related, in turn, to
different underlying testicular histological pathologies, ranging from
the complete absence of germ cells (Sertoli cell-only syndrome) to
hypospermatogenesis and maturation arrest. The alteration of
spermatogenesis can be the consequence of many causes, such as systemic
diseases, cryptorchidism, endocrinological disorders,
obstruction/absence of seminal pathways, or infections. However, the
cause of male infertility is unknown in up to 50% of cases, and until
recently relatively little research focused on the possible genetic
etiologies. The explosive growth of assisted reproduction techniques
and, in particular, of intracytoplasmic sperm injection (ICSI) (7) has
contributed to the development of such research. The study of Y
chromosome microdeletions is particularly important because of the
potential for transmission of genetic abnormalities to the offspring,
as these techniques bypass the physiological mechanisms related to
fertilization.
 |
II. Structure and Gene Content of the Y Chromosome
|
|---|
The Y chromosome is the smallest human chromosome and consists of
a short (Yp) and a long (Yq) arm. The pseudoautosomal regions (PARs),
which pair with the X chromosome during meiosis, are located at both
ends. The region outside the PARs that does not recombine is called the
nonrecombining region of the Y chromosome (NRY) (Fig. 1
). This part consists of several
repetitive sequences that may be homologs to regions on the X
chromosome or Y-specific. The Yp and the proximal part of Yq consist of
euchromatin, while the distal part of the long arm is made of
heterochromatin, and this region may vary in length to constitute about
one-half to two-thirds of Yq (Fig. 1
). Therefore, the Y chromosome long
arm may be cytogenetically divided in an euchromatic proximal region
(Yq11, subdivided into Yq11.1, 11.21, 11.22, and 11.23) and a
heterochromatic distal region (Yq12), whereas the euchromatic short arm
is called Yp11 (Fig. 2a
).

View larger version (10K):
[in this window]
[in a new window]
|
Figure 1. Schematic representation of the Y chromosome. The
PARs are represented in black, the euchromatic region in
white, and the heterochromatic region is
striped. Outside the PARs is the nonrecombining region
of the Y chromosome (NRY). Below are schematically represented the
phenotypes associated with alterations of the Y chromosome (sex
determination, risk of gonadoblastoma, small stature, and the three
spermatogenic failure loci AZFa, b, and
c). Yp and Yq, Short and long arm, respectively.
|
|

View larger version (35K):
[in this window]
[in a new window]
|
Figure 2. a, Representation of the
cytological bands of the Y chromosome. The short arm is called Yp11,
and the long arm is Yq11 (euchromatic region) and Yq12 (heterochromatic
region, striped). b, The seven intervals of the Vergnaud map of the Y
chromosome (8 ), where intervals 14 span the short arm and the
centromere, intervals 5 and 6 span the euchromatic region, and interval
7 spans the heterochromatic region. c, The 43 interval map of the Y
chromosome (9 ). On the right are represented a list of
genes mapped to the Y chromosome, the localization of
AZF regions and the corresponding candidate genes.
|
|
The absence of meiotic recombination within most parts of the Y
chromosome has hindered the construction of a linkage map of the
chromosome. Therefore, Y chromosome mapping has been based on naturally
occurring deletions. The initial Vergnaud interval map (8) divided the
Y chromosome into seven intervals (Fig. 2b
): the short arm and the
centromere contain intervals 14, distal to proximal; the euchromatic
part of Yq is represented by intervals 5 and 6, proximal to distal; the
heterochromatic region is defined as interval 7. Deletion interval 5
corresponds approximately to Yq11.21 through the middle part of
Yq11.22, and deletion interval 6 corresponds to the middle part of
Yq11.22Yq11.23. On this basis, Vollrath et al. (9) further
divided the seven-interval map in 43 subintervals, and this is the most
commonly used map (Fig. 2c
).
Initial attempts to draw a physical map of the Y chromosome led to the
isolation of overlapping yeast artificial chromosome (YAC) contigs (10, 11). More recent efforts in sequencing came from a systematic approach
within the Human Genome Project. With the major contribution of the two
leading centers involved in this project (Washington University and
Whitehead Institute), nearly 40% of the euchromatic region of the Y
chromosome (about 13 Mb out of the estimated 35 Mb) have been
sequenced, and more than 40 contigs have been isolated (data updated at
the end of June 2000; official site www.ncbi.nlm.nih.gov/genome). Even
if only half of them have been physically mapped to date, a finished
sequence of the entire Y chromosome will be available in the near
future. Together with this sequence map, more than 300 sequence-tagged
sites (STSs) have been generated and mapped. STSs are known sequences
of genomic DNA that can be amplified by PCR. These STSs may be specific
for a gene or may overlap anonymous regions of the Y chromosome, and
their use in Y deletion screening will be discussed in Section
VII.
Many genes on the Y chromosome have been identified only recently, and
perhaps novel genes will be described once sequencing has been
completed; so far, more than 30 genes and gene families are known. As
summarized by Yen (12), these genes can be classified into three groups
on the basis of their location on the Y, their copy number, and their
pattern of expression: 1) pseudoautosomal genes (such as
ASMTL, MIC2, and IL9R): their
sequences are identical on the Y and X chromosomes and, with few
exceptions, they are expressed in different tissues; 2) genes located
within X-Y homologous regions on the NRY (such as USP9Y,
DBY, and UTY): these have homologs on the X
chromosome encoding for proteins with very high amino acid identity.
These genes are ubiquitously expressed, although some have testis-
specific transcripts in addition to ubiquitous transcripts; 3)
Y-specific gene families (such as DAZ, CDY, and
TSPY); these are multicopy genes, widely distributed on the
Y chromosome or clustered within a small region, and they are expressed
only in the testis. One exception to this classification is
SRY, the gene that determines testis development: it is
Y-specific, but it is in single copy and has a different pattern of
expression, limited to the genital ridge and in fetal and adult Sertoli
cells and germ cells (13, 14, 15).
 |
III. The Azoospermia Factors
|
|---|
Tiepolo and Zuffardi in 1976 (3) were the first to hypothesize a
correlation between Y chromosome deletions and male infertility. These
authors examined the karyotype of 1,170 men; in six sterile males with
azoospermia they observed large deletions including the entire
heterochromatic region (Yq12) and an undefined amount of the adjacent
euchromatic part (Yq11). In two cases they demonstrated that the
fathers of the patients with deletions carried a normal Y chromosome,
indicating that these mutations were de novo events. This
suggested that the deletions were the cause of the azoospermia and they
postulated that a genetic factor located in Yq11 was important for male
germ cell development. This gene or gene cluster was defined as
"azoospermia factor" (AZF). However, the genetic
complexity of the AZF locus could be revealed only with the
development of STS- and YAC-based mapping. These analyses permitted the
detection of interstitial submicroscopic deletions not visible at the
cytogenetic level and detectable only by STS-PCR or Southern
hybridization. Such deletions are called microdeletions. Molecular
mapping analyses on patients with microdeletions have complicated the
original hypothesis of a single locus for spermatogenesis on Yq,
suggesting that three nonoverlapping regions in deletion intervals 5
and 6 may be deleted in infertile men. These spermatogenesis loci are
termed AZFa, AZFb, and AZFc (16) from
proximal to distal Yq. Furthermore, a fourth region (AZFd)
has been proposed between AZFb and AZFc (17), but
this finding must be confirmed. According to Vogt et al.
(18) (Fig. 2c
), AZFa is located at the proximal portion of
deletion interval 5 (subinterval 5C), AZFb spans from the
distal portion of deletion interval 5 to the proximal end of deletion
interval 6 (subinterval 5O6B), and AZFc is located at the
distal part of deletion interval 6 (subintervals 6C6E). Several genes
located in AZF regions are expressed in the testis and could
therefore be viewed as "AZF candidate genes." However,
based on studies of infertile patients, only a few genes can actually
be considered responsible for the AZF phenotype. The first
AZF-candidate gene was isolated in 1993 from a region
subsequently shown to correspond to AZFb. Two years later
the second AZF-candidate gene was identified from the
AZFc region. Both genes have been quite well studied both at
the molecular level and in terms of deletions in infertile patients.
The structure of AZFa and its gene content have only
recently been described, and analyses of this region in infertile males
suggested that two genes may be considered AZFa-candidate.
However, it should be noted that recent findings of many genes or gene
families outside the proposed AZF regions (19) suggest that
even this classification may be an oversimplified picture.
 |
IV. AZFb Region and Candidate Genes
|
|---|
A detailed sequence and gene map of AZFb is still not
available, and only nonoverlapping YAC and BAC clones have been
described. Even if the AZFb interval, as usually defined,
spans the subintervals 5O6B, the precise boundaries can differ and
its exact extension is unclear. This depends on different deletion
events between individuals and differences in screening procedures.
Microdeletions can remove AZFb alone, parts of
AZFb, or also include flanking regions (e.g.,
AZFc). The extent of deletions will obviously affect which
genes are removed: for example, deletions may remove the block
SMCY-XKRY-CDY2 (19), or the block
PRY-TTY2 (19) if they extend proximally or
distally, respectively.
To date, two genes have been mapped to subintervals 5O6B:
EIF1AY (translation-initiation factor 1A, Y isoform) and
RBMY (RNA binding motif on the Y). EIF1AY encodes
a Y isoform of eIF-1A, an essential translation initiation factor,
which has an X homolog and is ubiquitously expressed (19). Its role in
spermatogenesis is completely unknown, and no deletion specifically
removing this gene has been reported. Therefore, it is not considered
an AZFb-candidate gene. However, EIF1AY possesses
abundant testis-specific transcripts in addition to ubiquitous
transcripts (19), suggesting that this gene may contribute to the
AZFb phenotype.
RBMY was the first among the AZF candidate genes to be
identified and was cloned using patient DNA with a deletion in the
proximal region of interval 6 (20). Initially, two similar cDNAs were
isolated and named YRRM1 and 2 (Y-specific RNA
recognition motif) as they were predicted to encode a protein with an
RNA-binding motif. Subsequently it was shown that, in fact, there is a
family of 2050 genes and pseudogenes spread over both arms of the Y
chromosome, including a cluster within the AZFb region (21, 22), and YRRM was renamed "RBMY gene family"
(18). Such copies belong to at least six subfamilies (23, 24), but
RBMY-I is the only actively transcribed gene, and the
most functional copies are located on interval 6B (22), thus making it
a major candidate for the AZFb region (18). RBMY
is present as multiple copies in all eutherian ("placental")
mammals (25) and has an active X-borne homolog recently discovered both
in humans and marsupials (26, 27). It has been proposed that
RBMX retained a widespread function while RBMY
evolved a male-specific function in spermatogenesis.
The RBMY proteins (Fig. 3
) consist of a
single RNA-binding domain of the RRM (RNA recognition motif) type at
the N terminus and an auxiliary C-terminal domain containing four
37-amino acid (aa) repeats. This domain is known as the SRGY box, since
it contains a serine-arginine-glycine- tyrosine sequence (20, 28).
The gene consists of 12 exons, and the 37-residue repeats are encoded
by single exons (exons 710) (Fig. 3
), which show more than 85%
homology between their nucleotide sequences (28).

View larger version (9K):
[in this window]
[in a new window]
|
Figure 3. Genomic structure of the RBMY1 gene
and relative protein. Exons 24 (black) encode for the
RNA-binding domain of the protein, while each of exons 710 (111 bp)
encode for a single 37-aa SRGY box (striped). Identity
at the amino acid level between RBMY1 and mouse Rbm is shown in the
lower part of the figure.
|
|
Consistent with a role in spermatogenesis, the RBMY genes
are expressed only in the germline in the testis (spermatogonia,
spermatocytes, and round spermatids) (22). The actual function of RBMY
in male germ cell development is not clear; it is a nuclear protein
with dynamic modulations in its spatial location in the various
spermatogenic cells, suggesting that it possesses different functions
related to pre-mRNA splicing (29).
RBMY is considered the major AZFb candidate gene given
its testis specificity, its absence in a fraction of infertile
patients, and its homology with the mouse Rbm, deletion of
which causes male sterility (30, 31, 32). However, the multicopy nature of
this gene has complicated attempts to prove its role in human
spermatogenesis, as detrimental mutations in patients have not yet been
identified.
 |
V. AZFc Region and Candidate Genes
|
|---|
In an attempt to correlate severe spermatogenic defects with
frequent and consistent de novo microdeletions of the Y
chromosome, Reijo and colleagues (33) cloned a novel gene from the
distal portion of deletion interval 6 shown to be deleted in men with
azoospermia. This gene was named DAZ (deleted in
azoospermia) and was originally thought to be single copy, whereas it
is now clear that it is a member of a multigene family with more than
one copy on the Y chromosome, clustered in the AZFc region
(18, 34, 35, 36). Therefore, DAZ was renamed "DAZ
gene family" (18). The exact number of genes in the family is still
not clear, although at least three copies have been described by
Southern blotting or restriction mapping (34, 36, 37), and seven
copies, representing either active genes or pseudogenes, may be seen by
fiber-fluorescent in situ hybridization (35).
The structure of the DAZ gene is somewhat similar to that of
RMBY (Fig. 4
). DAZ
encodes a protein with a single RNA-binding domain at the N terminus
and a C-terminal domain containing an internally repeated sequence of
24 aa, the so-called DAZ repeats (33, 34). The DAZ
transcription unit appears to contain at least 16 exons and to span
about 42 kb. Exon 1 consists of the initiator codon, exons 25
encode the RNA-binding domain, and each of exons 7a7 g encodes a
single DAZ repeat (34).

View larger version (13K):
[in this window]
[in a new window]
|
Figure 4. Genomic structure of the DAZ gene
and relative protein. Exons 25 (black) encode for the
RNA-binding domain of the protein, while each of exons 7a7g (72 bp)
encode for a single 24-aa DAZ repeat (striped). Identity
at the amino acid level among DAZ, autosomal human DAZL1, mouse Dazl,
and Drosophila boule is shown in the lower
part of the figure.
|
|
The number of DAZ transcripts is unclear, since RT-PCR
studies showed that each individual carries two or more species of
DAZ transcripts, which differ in both the copy number and
the order of the DAZ repeats (37). Such DAZ
transcripts could have derived from the same gene through alternative
splicing or from different DAZ genes. Like RBMY,
DAZ is transcribed and translated into proteins only in male germ
cells (38, 39, 40, 41), even if a discrepancy exists between the findings of
Pages group (expression mainly in spermatogonia) (38) and that of
Vogts group (detection of DAZ proteins in late spermatids and sperm
tails) (39).
DAZ is found on the Y chromosome only in humans, Old World
monkeys, and apes (34, 42, 43, 44). In all other mammals it is represented
as an autosomally located, single copy gene (42, 45, 46, 47).
DAZ was acquired by the Y chromosome from an autosomal
homolog DAZL1 located on chromosome 3p24 and with a single
DAZ repeat (34, 48, 49, 50, 51) (Fig. 4
). A complete DAZL1
copy was transposed to the Y chromosome, a 2.4-kb genomic sequence
encompassing exons 7 and 8 was tandemly repeated, and, finally, the
whole transcription unit was amplified, giving rise to a multicopy gene
family (34, 37).
Although DAZ is not the only gene present in the distal Yq
interval 6 (19, 36, 52), its high prevalence of deletions in infertile
men makes it the major AZFc candidate. This possibility is
further strengthened by the high homology of DAZ with a
Drosophila male infertility gene, boule, mutation
of which causes spermatogenic arrest (53, 54). Furthermore, more recent
proof of the spermatogenic role of the DAZ gene product
arises from the observation that a human DAZ transgene is
capable of partially rescuing the sterile phenotype of a mouse knockout
for the homologous gene Dazl (55). However, most
difficulties in understanding the biological function of DAZ
and the genotype-phenotype relation probably arise from the multicopy
nature of this gene. Like RBMY, deletions of DAZ
in infertile patients are generally screened by PCR on genomic DNA
extracted from peripheral leukocytes. Therefore, only deletions
removing the whole of the DAZ gene cluster can be detected,
and intragenic deletions or deletions not involving all the
DAZ copies, as well as de novo point mutations in
affected patients, have yet to be discovered. Therefore, there is still
no definitive proof for a requirement of DAZ in
spermatogenesis.
Although a sequence map of AZFc is not yet available,
several genes other than DAZ have been mapped to this region
(19, 36): CDY1 (chromodomain Y 1), BPY2 (basic
protein Y 2), PRY (PTA-BL related Y), and TTY2
(testis transcript Y 2). The function of these genes is unknown, but
they share similar characteristics: they are in multiple copies on the
Y chromosome, they are expressed in the testis only, and they are Y
specific (19). In particular, three PRY and TTY2
genes have been identified in the proximal part of AZFc by
restriction mapping (36), and therefore they are probably not involved
in the spermatogenic disruption observed in patients with deletion
limited to DAZ. Two CDY1 genes map in the
AZFc region, one within the DAZ cluster and the
other one at the distal end (36). This finding is intriguing since at
least one CDY1copy in invariably absent in patients with
DAZ deletion. Therefore, CDY1 can be considered
an AZFc-candidate gene, but deletions removing this gene
specifically should be identified in patients to confirm this
hypothesis. No mapping and deletion data are available for
BPY2, which, therefore, is not included at present among the
AZFc- candidate genes.
 |
VI. AZFa Region and Candidate Genes
|
|---|
The most recent data suggest that more than one gene may be
responsible for the AZFa phenotype. However, the
characterization of the critical interval is still under way, and the
structure and gene constitution of this region have only recently been
described (19, 56, 57, 58, 59).This region contains three genes and has a
syntenic homology with the mouse
Sxrb interval (56) (Fig. 5
) located on the Y chromosome short arm,
deletion of which causes a severe spermatogenic impairment (60), very
similar to that observed in patients with the AZFa deletion.

View larger version (16K):
[in this window]
[in a new window]
|
Figure 5. The human AZFa region and the mouse
Sxrb interval. a, The AZFa region is
included in two nonoverlapping contigs, spanning more than 1.2 Mb. b,
Ten overlapping clones covering the AZFa region. c,
Localization of the three genes, USP9Y,
DBY, and UTY, with respect to the clones.
The arrows indicate the 5'3' orientation of the genes.
Note that UTY is not completely included in the clone
sequences and therefore the complete genomic structure of this gene is
still unknown. d, Transcription map of the mouse Sxrb
interval (spanning more than 900 kb), showing the syntenic homology
with the human AZFa interval: the block
Dffry, Dby, and Uty is
highly conserved between human and mouse. The numbers below the clones
and contigs represent the GenBank accession numbers.
|
|
The first gene identified in AZFa and subsequently shown to
be absent in infertile patients was DFFRY
(Drosophila fat facets related Y) (56, 61), recently renamed
USP9Y (ubiquitin-specific protease 9, Y chromosome). This
gene differs substantially from the other AZF candidate
genes DAZ and RBMY: it does not encode for an
RNA-binding protein, but seems to function as a C-terminal ubiquitin
hydrolase; it is a single copy gene, it has an X-homologous gene that
escapes X-inactivation, and it is ubiquitously expressed in a wide
range of tissues, rather than testis specific (19, 61) (Table 1
). Furthermore, a nine-residue peptide
derived from USP9Y has been shown to represent a new minor
histocompatibility antigen (H-Y antigen) presented by HLA-A1 and
involved in graft rejection (62). USP9Y occupies less than
half of the AZFa interval (57), while the majority of
infertile males carrying AZFa deletions show the absence of
this entire interval (16, 17, 18, 56, 63, 64, 65, 66). These findings suggested
that other gene(s) in this region may be responsible, either singly or
in combination with USP9Y, for the spermatogenic disruption
observed in AZFa-deleted patients. In fact, comparative
mapping studies showed that two further X-Y homologous genes are
located both in the Sxrb interval and
in AZFa, suggesting a possible role in spermatogenesis:
DBY (dead box on the Y) and UTY (ubiquitous TPR
motif on the Y) (19, 56). More recently, a novel expressed sequence
(AZFaT1) was mapped to this region (57). All such genes appear to be
ubiquitously expressed (19, 56, 57), therefore differing from their
mouse homologs, since mouse Dby, for example, is
expressed in several tissues (56, 57) and Dffry is testis
specific (61).
Initial studies on patients with deletions clearly limited to
AZFa suggested that deficiency of USP9Y or AZFaT1
or both cause male infertility and that the additional loss of
DBY may make the phenotype worse (57). Substantial proof for
USP9Y as a spermatogenesis gene has been recently published
(58), since a 4-bp deletion leading to a truncated protein was
discovered in an azoospermic man. An extensive deletion and expression
analysis of deletion intervals 5 C/D in highly selected infertile
patients allowed us to assemble a refined map of AZFa and to
demonstrate that DBY may represent the major spermatogenesis
gene of this region (59). It is more frequently deleted than
USP9Y , and it shows a testis-specific transcript in
addition to ubiquitous transcripts. The role for this gene in human
spermatogenesis is further supported by the significant homology of
DBY with the mouse protein PL10 (59), which is
testis-specific and expressed only in germ cells. DBY
consists of 17 exons (59) and encodes for a putative ATP-dependent RNA
helicase, as it belongs to the DEAD box proteins (67, 68). However, its
specific function in male germ cell development is still unknown.
 |
VII. Y Chromosome Microdeletions in Infertile Men
|
|---|
A. Methods of detection
Once a map of PCR markers covering the Y chromosome was assembled
(9, 69), the first searches for interstitial deletions in infertile men
were published (33, 70, 71). Such PCR markers are known as STSs, and to
date more than 300 have been physically mapped. Each STS detects known
sequences of genomic DNA, and its normal amplification by PCR indicates
the presence of this DNA sequence in the Y chromosome, while its
absence may indicate a deletion. An STS may be specific for a gene or
gene family or may detect anonymous sequences.
Most problems with the STS-PCR technique in screening for
microdeletions derive from the intrinsic nature of the Y chromosome,
which largely consists of repetitive elements and gene families widely
dispersed along the chromosome. As described by Kostiner et
al. (72), STS markers fall into three categories: 1) markers that
are single copy, such as those for SRY, USP9Y,
DBY, or UTY; these STSs are the most informative
given their specificity, and their absence indicates the loss of the
specific gene sequence; 2) markers that are multicopy but clustered in
a small region of the Y chromosome, such as those for the
DAZ gene family; in such a case a negative PCR result
indicates the loss of all members of the gene family. However, the
presence of a PCR band is less informative, since a normal
amplification merely indicates the presence of at least one gene copy
containing the marker sequence; 3) markers that are multicopy and
dispersed across large regions of the Y chromosome, such as those for
RBMY, CDY, or TSPY or other multicopy
gene families widely distributed on the chromosome; such repetitive
markers may be informative only when their absence indicates that very
large deletions of the Y chromosome have occurred, e.g.,
encompassing the entire Yq11.
Some markers may represent normal polymorphisms, as they may be absent
in both fertile and infertile patients. Polymorphic markers (such as
sY207 and sY272) are not useful in screening since their absence does
not represent significant deletions (73).
The STS-PCR technique is performed on genomic DNA extracted from
peripheral leukocytes; although rapid and simple, certain precautionary
measures should be applied in Y chromosome deletion screening before
assuming that a deletion exists; these measures include the use
of high quality DNA and internal and external positive and negative
controls (SRY or ZFX/ZFY gene, fertile male,
normal woman, and blank controls). Furthermore, European guidelines for
the molecular diagnosis of Y chromosome microdeletions (74) suggest
that the screening should be performed by multiplex PCR amplification
in which an internal control is amplified together with the selected
STS(s). The number of STSs to be used for a first screening is not well
established, and it varies substantially among the authors. However, as
a general rule, at least two or three STSs for each AZF
region should be used; if a deletion is found and confirmed, the number
of STSs should be increased to determine the deletion breakpoints.
Given the repetitive nature of some STSs and the quite frequent finding
of noncontiguous deletions, the results obtained by PCR should be
sometimes confirmed by Southern blotting experiments, especially if a
deletion not encompassing known spermatogenesis loci is found.
Furthermore, a deletion may be assumed to have a pathogenic role only
if it is demonstrated that it is of de novo origin and not
present in other fertile family members. Therefore, when available,
male relatives of patients should be analyzed.
The rapid progress in molecular biology technologies will allow us, in
the near future, to improve both the quality of the diagnosis and the
time needed for a Y deletion screening. For example, fluorescent PCR
will probably take the place of the conventional PCR method, since it
is 1,000-fold more sensitive, less time consuming, and would allow the
accurate testing of a small amount of DNA (e.g., for single
cell analysis). The analysis of Y chromosome deletions may also shift
to other more automated methods of detection, such as the microarrays
technique. However, time is needed to increase our knowledge of Yq
genes and mapping before this method may completely replace traditional
methods.
B. Selection of patients, genotype-phenotype relation, and origin
of deletions
The recent progress in molecular biology and Y chromosome mapping
has rendered the analysis of Y chromosome microdeletions in infertile
patients a routine diagnostic step. As a result, numerous studies on
this topic have been published: more than 4,800 infertile men have been
studied. Taken together, these data suggest that Y chromosome
microdeletions constitute one of the most common specific causes of
male infertility. In fact, based on studies from 1992, the overall
prevalence in infertile men is 8.2% (401/4,868) (16, 17, 33, 66, 70, 73, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102) (Fig. 6
). In contrast,
only 12 of 2,663 (0.4%) fertile males were found to carry a deletion,
probably reflecting polymorphisms, as discussed below. However, among
the various studies, remarkable differences in the prevalence of
microdeletions exist, ranging from 1% (85) to 35% (63), reflecting
above all different patient selection criteria. Therefore, the actual
incidence of clinically relevant microdeletions in infertile men is
still unclear. In this review we have summarized the studies published
up to May 2000, grouping them on the basis of the various patient
classifications used. In fact, male infertility is a heterogeneous
diagnostic category that may be classified only on clinical and
historical data, or on seminological data (normo-, oligo-, azoospermia)
and/or on testicular structure (Sertoli cell-only syndrome,
hypospermatogenesis, spermatogenic arrest, obstructive forms) (103).
Figure 6
shows the categories of infertile men, as described in the
original studies: in some reports other or nonuniform classifications
are used, and therefore only 3,640 of 4,868 patients may be clearly
grouped (16, 17, 33, 62, 63, 73, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98). To clarify a
genotype-phenotype relation, the different classification of infertile
patients is even more crucial.

View larger version (28K):
[in this window]
[in a new window]
|
Figure 6. Summary of the literature on Yq microdeletions in
infertile males from 1992 to May 2000 (16 17 33 63 64 66 70 73 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 ). The first category at the top of the figure
represents all patients published, while the other categories have been
grouped from homogeneous studies in which a clear description of
patients was reported. The prevalence of Yq microdeletions was
calculated regardless of the number of STSs used or genes analyzed.
|
|
Most studies have focused on azoospermic and severely oligozoospermic
men (sperm count <5 x 106/ml) with a
total of 1,491 patients published (deletion in 156 subjects, prevalence
of 10.5%), and more recently on ICSI-candidates (32/850, 3.8%).
However, also in such categories of infertile men we must distinguish
between true azoospermic and severely oligozoospermic men, and among
patients with idiopathic infertility, known causes of spermatogenic
alteration, obstructive azoospermia, or unselected patients. Figure 6
clearly shows that the prevalence of deletions increases with more
strict patient selection criteria: in unselected oligozoospermic men
the prevalence is 2.9% but rises to 11.6% if idiopathic
oligozoospermia is selected, and to 14.3% in idiopathic severe
oligozoospermia; similarly, unselected azoospermic patients show a
deletion rate of 7.3%, but if we exclude obstructive azoospermia the
prevalence rises to 10.5%, and to 18% if only idiopathic forms are
considered. Furthermore, if patients are selected on the basis of their
testicular structure, the prevalence is 24.7% in idiopathic severe
oligozoospermia with a testicular picture of severe
hypospermatogenesis, and 34.5% in idiopathic azoospermia with a
testicular histology of Sertoli cell-only syndrome. A further
consideration is that the prevalence in patients with a sperm count
greater than 5 x 106/ml is very low
(0.7%), suggesting that Y deletions most frequently determine severe
damage in sperm production. As shown in Table 2
and considering only homogeneous
studies in which sperm count of infertile patients is reported (16, 33, 63, 64, 73, 76, 78, 79, 80, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94), deletions more frequently determine
azoospermia (84.3%) than severe oligozoospermia (14.1%) or moderate
oligozoospermia (1.6%). These data further strengthen the hypothesis
that Y chromosome microdeletions produce a severe loss of spermatogenic
cells up to their complete absence, and that a deletion screening
should be offered mostly in azoospermic and severely oligozoospermic
patients.
The relative prevalence of deletions in AZFa, b,
and c regions in infertile men, as results from the analysis
of homogeneous studies, is shown in Table 3
. Deletions most frequently involve the
AZFc region including DAZ (59.6%), less
frequently the AZFb region including RBMY
(15.8%), and in only 4.9% of cases the AZFa interval.
Larger deletions involving two or three AZF regions are
observed in 13.6% of patients, while in 6% of cases the deletions are
located in regions not overlapping the AZF intervals. These
data suggest a predominant role in spermatogenesis of the
DAZ gene family with respect to the other AZF
candidates. However, such results may also reflect our current
knowledge of the AZF genes, and we have, for example,
detected a high prevalence of deletions in the AZFa region
in selected infertile patients affected by idiopathic severe
testiculopathies (9/133, 6.8%) (59). The higher incidence of deletions
in AZFc may be due to the fact that it is nearly always
included in the screening program while AZFa and
AZFb are more rarely investigated. Furthermore, the problems
in analyzing multicopy genes may explain the low rate of deletion
found, for example, for RBMY. The higher frequency of
deletion in AZFc may also be due to the presence of long
direct and inverted repeats in this region (36), rendering this
interval particularly prone to deletion events.
The phenotypes associated with deletions are variable, and in general
there is no clear correlation between the localization of the deletions
(AZFa, b, or c) and the clinical
phenotype. Although one group reported different phenotypes in
association with each of the three deleted regions (16), such
correlations have not been observed by others. The analysis of the
literature (Table 4
) shows that
AZFc deletion may be associated both with azoospermia (54%)
and severe oligozoospermia (46%), and the testicular histology (where
available) may vary from Sertoli cell-only to spermatogenic arrest and
hypospermatogenesis. Tubules with variable defects may be found in the
same individual. The absence of DAZ appears therefore to be
insufficient to determine the complete loss of the spermatogenic line,
but rather seems to produce a reduction in the number of these cells or
an alteration of their maturation process. It is possible that the
testicular damage caused by DAZ deletions is progressive and
that oligozoospermic patients may become azoospermic later in life.
Alternatively, small differences in the extent of apparently identical
DAZ deletions may explain this variable phenotype, but none
of these hypotheses have yet been demonstrated.
Deletions in AZFa and in AZFb cause azoospermia
in two-thirds of all cases, and more rarely severe oligozoospermia.
Therefore, the phenotype associated with such deletions seems to be
more severe than that observed in AZFc-deleted patients,
even if in some cases an AZFb deletion (above all not
including RBMY) may be associated with moderate
oligozoospermia. The testicular histology of AZFa patients
with azoospermia always shows Sertoli cell-only, while in patients with
severe oligozoospermia it resembles severe hypospermatogenesis,
i.e., no maturation arrest is seen. Our study on the
AZFa region (59) showed that the loss of DBY may
be associated both with Sertoli cell-only syndrome and severe
hypospermatogenesis, suggesting that this gene might regulate the first
phases of the spermatogenic process or the activity of the stem cells.
On the contrary, the deletion of USP9Y (59) as well as its
mutation (58) have been found to determine only severe
hypospermatogenesis. AZFb patients could have more variable
defects, and in about half of cases a spermatogenic arrest is observed.
The variable spermatogenic alterations observed in AZFb
patients may indicate multiple functions of RBMY during
spermatogenesis or, alternatively, that other genes located in this
region may act in combination to RBMY and that their
presence or absence modulates the phenotype.
The variable phenotype observed both in patients with AZFb
and in patients with AZFc deletions may be explained by
different hypotheses:
1. Different extension of the deletion. Deletions may completely remove
AZFb or AZFc or they may be smaller, extending,
for example, only one gene or gene cluster or few STS markers. It can
be speculated that larger deletions may be associated with a more
severe phenotype. However, neither a review of the literature nor our
experience support this hypothesis. For example, deletions removing
only DAZ and not extending to flanking regions may cause
both azoospermia and severe oligozoospermia. Furthermore, the combined
deletion of DAZ and CDY1 do not seem to cause a
phenotype worse than that observed in patients who retained the distal
CDY1 copy (A. Ferlin, E. Moro, A. Rossi, and C. Foresta,
submitted). However, it should be kept in mind that apparently
identical deletions, as assessed by STS-PCR, may be actually slightly
different in size and this may, at least in part, justify a different
phenotype.
2. Role of homologous genes and genetic background. Each of the
AZF candidate gene has homologs on the X chromosome
(DBX, USP9X, RBMX) or on autosomes
(DAZL1), as many other genes on the Y chromosome have
(e.g., EIF1AY has a homolog on the X chromosome,
and CDY has a homolog on chromosome 6). Even if no direct
evidence of a role of these genes in spermatogenesis exists, their
status may modify the phenotypic expression of Y-deleted patients. This
is particularly suggestive for DAZL1/DAZ, since
DAZL1 is expressed exclusively in the gonads and may
therefore synergistically act in combination with DAZ during
spermatogenesis. Therefore, the genetic background may modulate the
phenotypic effect of a given deletion, and the absence of an
AZF gene may be differently compensated by other genes of
the family.
3. Progression of the spermatogenic failure. It has been suggested that
Yq microdeletions could result in progressive worsening of sperm
production (88, 104, 116), and that oligozoospermic men may become
azoospermic with time. This is an intriguing hypothesis that, if
confirmed, has important prognostic consequences, since
cryoconservation of spermatozoa in these cases could avoid more
invasive techniques, such as ICSI, in the future.
From the analysis of the literature the only clear correlation that has
been found is with very large deletions involving more than one
AZF locus. These deletions are associated with the most
severe phenotype, and this is exemplified by the invariable finding of
azoospermia and Sertoli cell-only in patients with deletions of
AZFa-c. Such large deletions probably show the additional
effects of each single gene deletion. These data are also in agreement
with the report that smaller deletions are associated with finding some
sperm at TESE (testicular sperm extraction) during ICSI treatments,
while larger deletions are not (92).
For 401 Y-deleted patients, 136 male relatives (father and/or brothers)
were analyzed, and in 95% of cases (394/401) no microdeletions were
found (Fig. 6
). In the other seven cases a deletion was found both in
the father and in his infertile son (16, 17, 70, 73, 105); in some
cases the deletion involved STS markers subsequently shown to represent
polymorphisms, but in other descriptions the father was found to carry
a clinically relevant deletion of apparently identical size to that of
the son, or even a smaller deletion (105). These findings demonstrate
that such nonpolymorphic deletions can, in rare cases, be passed on
from father to son, and may become larger (with possible additional
negative effects). In most cases, these naturally occurring
transmissions involved the AZFc region, and this was
confirmed by a recent study that reported an identical AZFc
deletion including DAZ in four infertile brothers and their
father (104). The father was azoospermic at the time of analysis, but
he evidently possessed some degree of fertility when he fathered,
suggesting that the loss of germ cells caused by DAZ
deletions may be progressive over the years. However, as seen above, it
is possible that apparently identical deletions, as determined by STS
analysis, are actually different in size, and that the father, for
example, could have a smaller deletion than his infertile sons.
Alternatively, a different exposure to the environment or a different
genetic background may have determined the phenotypic variation.
Apart from the few inherited cases described above, the major part of
Yq deletions are of de novo origin, which means that they
are not present in the fathers DNA and probably originated in the
germ line of the father (106). The spermatogenic stage at which the
deletion occurs is not known: even if primary spermatocytes in meiotic
prophase are probably the most sensitive cells, deletions may arise
during other steps of DNA replication or even during spermiogenesis
(106). The mechanism by which a Y deletion arises is not clear, since
unlike autosomes, only limited parts of the Y chromosome pair with the
X chromosome and no recombination occurs within the AZF
regions. Therefore, it has been proposed that Y deletions are likely to
be the consequence of the presence of many highly repeated DNA elements
causing illegitimate intrachromosomal recombination. Specific genetic
or environmental factors may predispose certain individuals to produce
higher proportions of sperm with de novo deletions that may
compete successfully with nondeleted spermatozoa to fertilize an egg
and give rise to a Y-deleted child. This hypothesis could only be
demonstrated by deletion analysis on single spermatozoa of the fathers.
The other stage at which a Y deletion could originate is in the
fertilized egg or during the first embryonic developmental phases of
the infertile son (106). This should give rise to a mosaicism (normal Y
chromosome in leukocytes, deleted Y chromosome in the germ line) and
also this hypothesis should be analyzed in the future. Whatever is the
case, the de novo origin of a Y deletion in an infertile
patient is fundamental to assess its pathogenic role in determining the
spermatogenic disruption.
The causative role of Y chromosome microdeletions in spermatogenic
impairment is also supported by the evidence that male infertility
caused by well known etiologies, such as Klinefelters syndrome,
previous chemo-radiotherapy, orchitis, or testicular trauma, are rarely
associated with Y deletions (63, 107). However, a recent study (83)
reported a high prevalence of deletion also in azoospermia and severe
oligozoospermia associated with other apparent causes (5/72, 6.9%).
These data suggest that such severe testiculopathies may actually be
due to Y chromosome deletions. In particular, sporadic observations
showed that patients with cryptorchidism or varicocele and azoospermia
or severe oligozoospermia could carry deletions (17, 73, 80, 88, 93).
We reported a high incidence of deletion in unilateral ex-cryptorchid
patients affected by azoospermia or severe oligozoospermia due to
severe bilateral testicular damage (11/40, 27.5%), while we found no
deletions in ex-cryptorchid men with normal function of the descended
testis (108). Furthermore, it is possible that the severe
testiculopathy caused by Y chromosome microdeletion may have rendered
the testis unresponsive to the normal stimuli that regulate testicular
descent. These results suggest that the bilateral testiculopathy
observed in patients with unilateral cryptorchidism may be related to
the deletion of the Y chromosome and not to the abnormal location of
the testis. Similarly, seven of 40 (17.5%) patients affected by left
varicocele and severe oligozoospermia sustained by severe
hypospermatogenesis were found to have a Y deletion, while no
abnormalities were detected in patients with varicocele and mild
oligozoospermia (109). Also in this group of patients, the bilateral
testicular damage is due to the underlying genetic anomaly and not to
varicocele itself. The finding of Y chromosome microdeletions in such
highly selected patient groups strongly suggests that the phenotype
associated with a Y chromosome microdeletion may be also cryptorchidism
and varicocele other than idiopathic infertility. All patients
affected by severe testiculopathies should be screened for
microdeletions, regardless of other concomitant causes of testicular
damage (110).
From the clinical point of view, hormonal values and testicular volumes
in Y-deleted patients indicate a severe testiculopathy involving only
the spermatogenic system. In fact, the testes are generally reduced in
size, FSH concentrations are high, and LH and testosterone plasma
levels are within the normal range. The major part of studies reported
no significant differences in testicular volumes and FSH levels between
patients affected by severe testiculopathy with and without Y
deletions. However, one study reported that FSH levels in patients with
deletions, although higher than controls, were lower with respect to
patients with similar tubular alterations but without deletions (80),
and another study showed that Y-deleted patients had normal FSH plasma
concentrations (87). If a difference in hormonal concentrations between
deleted and nondeleted patients really exists, further studies are
necessary to understand the mechanisms responsible for such
differences.
As previously noted (111), there is no correlation between the
frequency of microdeletions detected and the number of STSs analyzed.
For example, if we consider only homogenous studies in which idiopathic
azoospermic and oligozoospermic patients are reported (63, 64, 73, 80, 81, 82, 83, 87, 94, 95, 101), the number of STSs used varies from eight
(80) to 85 (73), but the prevalence of deletions does not increase if
more STSs are used (P = 0.9, not significant).
Therefore, at the present time, the diagnostic performance is not
improved by using large sets of STSs, and good results can be
obtained using two to three STS markers for each AZF region,
as recently suggested (74). What is really important for a careful
diagnosis is that the panels of STS chosen amplify tracts of the Y
chromosome containing genes that are known to be deleted specifically
in infertile men and are not polymorphic. Furthermore, research in this
field is growing and if a gene of the Y chromosome becomes a strong
spermatogenesis candidate it should be included in the screening; in
general, it is better to choose STS markers that amplify specific
regions of a gene than those amplifying anonymous tracts of the Y
chromosome.
C. The concern of assisted reproduction techniques
ICSI is the direct introduction of a spermatozoon into an oocyte
to achieve fertilization and pregnancy when the number of spermatozoa
in the ejaculate is very low or even absent. In the latter case, ICSI
can be performed using spermatozoa obtained from the epididymis or
directly extracted from testicular tissue. Furthermore, techniques of
spermatid injection into oocytes may be performed and first term
pregnancies have been achieved in humans (112, 113). Despite the
world-wide diffusion of ICSI in recent years, the possible risks that
might ensue from its indiscriminate use have been considered only
recently. These concerns arose especially with the recent advances in
genetically determined male infertility (114, 115). ICSI arouses more
fears of the transmission of genetic abnormalities to offspring than
other forms of assisted reproduction techniques because it bypasses all
the physiological mechanisms related to fertilization, which need an
active motile spermatozoon to undergo normal capacitation and acrosome
reaction and to start all mechanisms required to penetrate the oocyte.
By bypassing these steps, ICSI allows an altered spermatozoon to
fertilize an oocyte, thus increasing the risk of genetic defects in the
offspring. In other words, a genetic defect giving rise to abnormal
spermatogenesis that can be surmounted by ICSI could be transmitted to
the children produced. The concerns are most remarkable for male
infertility related to Y chromosome microdeletions, since Y-deleted
patients are strong candidates for ICSI, as in most cases spermatozoa
or spermatids suitable for the procedure can be recovered from semen or
the testis, but all male offspring will invariably inherit the deleted
Y chromosome from the father.
Mulhall et al. (90) first reported the fertilization and
pregnancy achieved utilizing ICSI with testicular spermatozoa from
azoospermic patients presenting deletions in the DAZ region,
suggesting that Y-deleted spermatozoa are fully competent for
fertilization. Subsequently, the same group reported the birth via ICSI
of male offspring from an AZFc-deleted man (116), and other
authors reported similar findings (117, 118). Following Mendelian
expectations, all the boys inherited their fathers deleted Y
chromosome. These observations provide a concrete foundation for
alerting couples to the likelihood of transmitting infertility-causing
Y deletions by ICSI. Furthermore, since Y microdeletions are the most
common molecularly defined causes of spermatogenic failure, one might
expect that significant numbers of Y-deleted boys will be fathered
through ICSI. From the analysis of the literature (Fig. 6
), the
prevalence of Y chromosome microdeletions in the ICSI candidate group
is relatively low (3.8%), but it should be kept in mind that all
severely oligozoospermic and azoospermic men with spermatozoa or
spermatids in the testis represent the best candidates for this
procedure, and the prevalence in these groups of patients is much
higher. These findings provide a compelling rationale for the screening
of all infertile men before ICSI.
Y-deleted spermatozoa may also transmit the deletion to male offspring
via in vitro fertilization (IVF). In fact, it has been
demonstrated that spermatozoa from an oligozoospermic subject carrying
a Yq deletion are able to fertilize oocytes in vitro (119),
suggesting that sperm carrying a deletion possess all the
characteristics required to regulate capacitation, acrosome reaction,
and the ability to penetrate and fertilize the oocyte. These findings
are also supported by the evidence that Y deletion may be transmitted
from father to sons also by spontaneous conception (16, 105, 106), even
if very rarely (see above). In our opinion, Yq microdeletion analysis
should be considered not only in patients undergoing ICSI, but also
when undergoing other IVF programs.
The actual consequence of inheriting a Y deletion is still not clear,
and we will have to wait until babies with the Y deletion conceived by
IVF/ICSI become adult. Since descriptions of larger deletions in the
sons with respect to the fathers have been reported (105), careful
counseling of patients is mandatory, especially as to the risk of
inheriting a deletion the clinical consequences of which are presently
unknown, but, at the very least, include infertility. An identical
deletion may be associated with different phenotypes, and therefore we
cannot foresee the actual defects in the sons. Of greater concern is
the possibility that additional unknown genetic problems may be present
in infertile men whom nature has deemed unable to reproduce until now.
Obviously, after extensive counseling, the couple must make the final
decision about further treatment, but important ethical considerations
arise since severe male infertility has now become a hereditary
disorder. The clinician should be aware that the use of such techniques
may lead to an increase in the number of infertile subjects in future
populations. The primary rationale of medically assisted reproduction
is the opportunity for parents to have a healthy baby, and a mandatory
condition for achieving this goal is that the genetic characteristics
of the gametes must be normal.
 |
VIII. Conclusions
|
|---|
The rapid growth of molecular biology has determined that
microdeletions of the Y chromosome represent an important cause of male
infertility and the most frequent genetic etiology of severe
testiculopathy. Such findings are fundamental both for a careful
diagnosis of male infertility and for its treatment, and Y chromosome
screening is now a reality in the major andrological and infertility
centers. The detection of a deletion in an infertile man provides a
proper diagnosis of the disease, allows the clinician to avoid
empirical, unnecessary, and often expensive treatments to improve
fertility (e.g., hormonal treatments), and has important
ethical consequences if the patient is a candidate for assisted
reproduction techniques. Furthermore, it is now clear that a molecular
diagnostic test of Y chromosome microdeletions should be at
least performed in all men with a sperm concentration of less that
5 x 106/ml, regardless of the presence of
other apparent concomitant causes of testicular damage, such as
varicocele or cryptorchidism.
The identification of the actual role played by the
AZF-candidate genes in spermatogenesis will provide
significant advances to our understanding of the biology of
spermatogenesis, as well as the analysis of novel Y-chromosomal genes
with a potential role in male germ cell development will clarify other
important features of this important chromosome.
 |
Footnotes
|
|---|
Address reprint requests to: Carlo Foresta, M.D.,
University of Padova, Department of Medical and Surgical Sciences,
Clinica Medica 3, Via Ospedale 105, 35128 Padova, Italy.
1 This work was supported by Telethon Grant E.C0988 (Italy) and
Ministry of University and Scientific and Technological Research
(MURST) 1999. 
 |
References
|
|---|
-
Sinclair AH, Berta P, Palmer MS, Hawkins JR,
Griffiths BL, Smith MJ, Foster JW, Frischauf AM, Lovell-Badge R,
Goodfellow PN 1990 A gene from the human sex-determining region
encodes a protein with homology to a conserved DNA-binding motif.
Nature 346:240244[CrossRef][Medline]
-
Burgoyne PS 1998 The mammalian Y chromosome: a
new perspective. Bioessays 20:363366[CrossRef][Medline]
-
Tiepolo L, Zuffardi O 1976 Localization of
factors controlling spermatogenesis in the nonfluorescent portion of
the human Y chromosome long arm. Hum Genet 34:119124[CrossRef][Medline]
-
Clermont Y 1966 Renewal of spermatogonia in man.
Am J Anat 118:509524[CrossRef][Medline]
-
Dym M 1994 Spermatogonial stem cells of the
testis. Proc Natl Acad Sci USA 91:1128711289[Free Full Text]
-
De Kretser DM, Baker HWG 1999 Infertility in
men: recent advances and continuing controversies. J Clin
Endocrinol Metab 84:34433450[Free Full Text]
-
Palermo G, Joris H, Devroey P, Van Steirteghem
AC 1992 Pregnancies after intracytoplasmic injection of single
spermatozoon into an oocyte. Lancet 340:1718[CrossRef][Medline]
-
Vergnaud G, Page DC, Simmler MC, Brown L, Rouyer F,
Noel B, Botstein D, de la Chapelle A, Weissenbach J 1986 A
deletion map of the human Y chromosome based on DNA hybridization.
Am J Hum Genet 38:109124[Medline]
-
Vollrath D, Foote S, Hilton A, Brown LG, Beer-Romero
P, Bogan JS, Page DC 1992 The human Y chromosome: a 43-interval
map based on naturally occurring deletions. Science 258:5259[Abstract/Free Full Text]
-
Jones MH, Khwaja OS, Briggs H, Lambson B, Davey PM,
Chalmers J, Zhou CY, Walker EM, Zhang Y, Todd C, Ferguson-Smith MA,
Affara NA 1994 A set of ninety-seven overlapping yeast artificial
chromosome clones spanning the human Y chromosome euchromatin. Genomics 24:266275[CrossRef][Medline]
-
Affara N, Bishop C, Brown W, Cooke H, Davey P, Ellis
N, Graves JM, Jones M, Mitchell M, Rappold G, Tyler-Smith C, Yen P, Lau
Y-FC 1996 Report of the Second International Workshop on
Y-Chromosome Mapping 1995. Cytogenet Cell Genet 73:3372[Medline]
-
Yen PH 1999 Advances in Y chromosome mapping.
Curr Opin Obstet Gynecol 11:275281[CrossRef][Medline]
-
Koopman P 1999 Sry and Sox9: mammalian
testis-determining genes. Cell Mol Life Sci 55:839856[Medline]
-
Jeske YW, Bowles J, Greenfield A, Koopman P 1995 Expression of a linear Sry transcript in the mouse genital ridge. Nat
Genet 10:480482[CrossRef][Medline]
-
Salas-Cortes L, Jaubert F, Barbaux S, Nessmann C, Bono
MR, Fellous M, McElreavey K, Rosemblatt M 1999 The human SRY
protein is present in fetal and adult Sertoli cells and germ cells. Int
J Dev Biol 43:135140[Medline]
-
Vogt PH, Edelmann A, Kirsch S, Henegariu O, Hirschmann
P, Kiesewetter F, Kohn FM, Schill WB, Farah S, Ramos C, Hartmann M,
Hartschuh W, Meschede D, Behre HM, Castel A, Nieschlag E, Weidner W,
Grone HJ, Jung A, Engel W, Haidl G 1996 Human Y chromosome
azoospermia factors (AZF) mapped to different subregions in Yq11. Hum
Mol Genet 5:933943[Abstract/Free Full Text]
-
Kent-First M, Muallem A, Shultz J, Pryor J, Roberts K,
Nolten W, Meisner L, Chandley A, Gouchy G, Jorgensen L, Havighurst T,
Grosch J 1999 Defining regions of the Y-chromosome responsible for
male infertility and identification of a fourth AZF region (AZFd) by
Y-chromosome microdeletion detection. Mol Reprod Dev 53:2741[CrossRef][Medline]
-
Vogt PH, Affara N, Davey P, Hammer M, Jobling MA, Lau
YF, Mitchell M, Schempp W, Tyler-Smith C, Williams G, Yen P, Rappold
GA 1997 Report of the Third International Workshop on Y Chromosome
Mapping 1997. Cytogenet Cell Genet 79:120[Medline]
-
Lahn BT, Page DC 1997 Functional coherence of the
human Y chromosome. Science 278:675680[Abstract/Free Full Text]
-
Ma K, Inglis JD, Sharkey A, Bickmore WA, Hill RE,
Prosser EJ, Speed RM, Thomson EJ, Jobling M, Taylor K, Wolfe J, Cooke
HJ, Hargreave TB, Chandley AC 1993 A Y chromosome gene family with
RNA-binding protein homology: candidates for the azoospermia factor AZF
controlling human spermatogenesis. Cell 75:12871295[CrossRef][Medline]
-
Prosser J, Inglis JD, Condie A, Ma K, Kerr S, Thakrar
R, Taylor K, Cameron JM, Cooke HJ 1996 Degeneracy in human
multicopy RBM (YRRM), a candidate spermatogenesis gene. Mamm Genome 7:835842[CrossRef][Medline]
-
Elliott DJ, Millar MR, Oghene K, Ross A, Kiesewetter
F, Pryor J, McIntyre M, Hargreave TB, Saunders PT, Vogt PH, Chandley
AC, Cooke H 1997 Expression of RBM in the nuclei of human germ
cells is dependent on a critical region of the Y chromosome long arm.
Proc Natl Acad Sci USA 94:38483853[Abstract/Free Full Text]
-
Chai NN, Salido EC, Yen PH 1997 Multiple
functional copies of the RBM gene family, a spermatogenesis candidate
on the human Y chromosome. Genomics 45:355361[CrossRef][Medline]
-
Chai NN, Zhou H, Hernandez J, Najmabadi H, Bhasin S,
Yen PH 1998 Structure and organization of the RBMY genes on the
human Y chromosome: transposition and amplification of an ancestral
autosomal hnRNPG gene. Genomics 49:283289[CrossRef][Medline]
-
Delbridge ML, Harry JL, Toder R, ONeill RJ, Ma K,
Chandley AC, Graves JA 1997 A human candidate spermatogenesis
gene, RBM1, is conserved and amplified on the marsupial Y chromosome.
Nat Genet 15:131136[CrossRef][Medline]
-
Delbridge ML, Lingenfelter PA, Disteche CM, Graves
JA 1999 The candidate spermatogenesis gene RBMY has a homologue on
the human X chromosome. Nat Genet 22:223224[CrossRef][Medline]
-
Mazeyrat S, Saut N, Mattei MG, Mitchell MJ 1999 RBMY evolved on the Y chromosome from a ubiquitously transcribed X-Y
identical gene. Nat Genet 22:224226[CrossRef][Medline]
-
Najmabadi H, Chai N, Kapali A, Subbarao MN, Bhasin D,
Woodhouse E, Yen P, Bhasin S 1996 Genomic structure of a
Y-specific ribonucleic acid binding motif-containing gene: a putative
candidate for a subset of male infertility. J Clin Endocrinol
Metab 81:21592164[Abstract]
-
Elliott DJ, Oghene K, Makarov G, Makarova O, Hargreave
TB, Chandley AC, Eperon IC, Cooke HJ 1998 Dynamic changes in the
subnuclear organisation of pre-mRNA splicing proteins and RBM during
human germ cell development. J Cell Sci 111:12551265[Abstract]
-
Elliott DJ, Ma K, Kerr SM, Thakrar R, Speed R,
Chandley AC, Cooke H 1996 An RBM homologue maps to the mouse Y
chromosome and is expressed in germ cells. Hum Mol Genet 5:869874[Abstract/Free Full Text]
-
Laval SH, Glenister PH, Rasberry C, Thornton CE,
Mahadevaiah SK, Cooke HJ, Burgoyne PS, Cattanach BM 1995 Y
chromosome short arm-Sxr recombination in XSxr/Y males causes deletion
of Rbm and XY female sex reversal. Proc Natl Acad Sci USA 92:1040310407[Abstract/Free Full Text]
-
Mahadevaiah SK, Odorisio T, Elliott DJ, Rattigan A,
Szot M, Laval SH, Washburn LL, McCarrey JR, Cattanach BM, Lovell-Badge
R, Burgoyne PS 1998 Mouse homologues of the human AZF candidate
gene RBM are expressed in spermatogonia and spermatids, and map to a Y
chromosome deletion interval associated with a high incidence of sperm
abnormalities. Hum Mol Genet 7:715727[Abstract/Free Full Text]
-
Reijo R, Lee TY, Salo P, Alagappan R, Brown LG,
Rosenberg M, Rozen S, Jaffe T, Straus D, Hovatta O, de la Chapelle A,
Silber S, Page DC 1995 Diverse spermatogenic defects in humans
caused by Y chromosome deletions encompassing a novel RNA-binding
protein gene. Nat Genet 10:383393[CrossRef][Medline]
-
Saxena R, Brown LG, Hawkins T, Alagappan RK, Skaletsky
H, Reeve MP, Reijo R, Rozen S, Dinulos MB, Disteche CM, Page DC 1996 The DAZ gene cluster on the human Y chromosome arose from an
autosomal gene that was transposed, repeatedly amplified and pruned.
Nat Genet 14:292299[CrossRef][Medline]
-
Glaser B, Yen PH, Schempp W 1998 Fibre-fluorescence in situ hybridization unravels apparently
seven DAZ genes or pseudogenes clustered within a Y-chromosome region
frequently deleted in azoospermic males. Chromosome Res 6:481486[CrossRef][Medline]
-
Yen PH 1998 A long-range restriction map of
deletion interval 6 of the human Y chromosome: a region frequently
deleted in azoospermic males. Genomics 54:512[CrossRef][Medline]
-
Yen PH, Chai NN, Salido EC 1997 The human DAZ
genes, a putative male infertility factor on the Y chromosome, are
highly polymorphic in the DAZ repeat regions. Mamm Genome 8:756759[CrossRef][Medline]
-
Menke DB, Mutter GL, Page DC 1997 Expression of
DAZ, an azoospermia factor candidate, in human spermatogonia. Am J
Hum Genet 60:2372341[Medline]
-
Habermann B, Mi HF, Edelmann A, Bohring C, Backert IT,
Kiesewetter F, Aumuller G, Vogt PH 1998 DAZ (deleted in
azoospermia) genes encode proteins located in human late spermatids and
in sperm tails. Hum Reprod 13:363369
-
Ferlin A, Moro E, Onisto M, Toscano E, Bettella A,
Foresta C 1999 Absence of testicular DAZ gene expression in
idiopathic severe testiculopathies. Hum Reprod 14:22862292[Abstract/Free Full Text]
-
Lee JH, Lee DR, Yoon SJ, Chai YG, Roh SI, Yoon HS 1998 Expression of DAZ (deleted in azoospermia), DAZL1 (DAZ-like) and
protamine-2 in testis and its application for diagnosis of
spermatogenesis in non-obstructive azoospermia. Mol Hum Reprod 4:
827834
-
Cooke HJ, Lee M, Kerr S, Ruggiu M 1996 A murine
homologue of the human DAZ gene is autosomal and expressed only in male
and female gonads. Hum Mol Genet 5:513516[Abstract/Free Full Text]
-
Gromoll J, Weinbauer GF, Skaletsky H, Schlatt S,
Rocchietti-March M, Page DC, Nieschlag E 1999 The old world monkey
DAZ (deleted in azoospermia) gene yields insights into the evolution of
the DAZ gene cluster on the human Y chromosome. Hum Mol Genet 8:20172024[Abstract/Free Full Text]
-
Carani C, Gromoll J, Brinkworth MH, Simoni M,
Weinbauer GF, Nieschlag E 1997 cynDAZLA: a cynomolgus monkey
homologue of the human autosomal DAZ gene. Mol Hum Reprod 3:479483[Abstract/Free Full Text]
-
Houston DW, Zhang J, Maines JZ, Wasserman SA, King
ML 1998 A Xenopus DAZ-like gene encodes an RNA
component of germ plasm and is a functional homologue of
Drosophila boule. Development 125:171180[Abstract]
-
Reijo R, Seligman J, Dinulos MB, Jaffe T, Brown LG,
Disteche CM, Page DC 1996 Mouse autosomal homolog of DAZ, a
candidate male sterility gene in humans, is expressed in male germ
cells before and after puberty. Genomics 35:346352[CrossRef][Medline]
-
Maiwald R, Luche RM, Epstein CJ 1996 Isolation of
a mouse homolog of the human DAZ (deleted in azoospermia) gene. Mamm
Genome 7:628
-
Shan Z, Hirschmann P, Seebacher T, Edelmann A, Jauch
A, Morell J, Urbitsch P, Vogt PH 1996 A SPGY copy homologous to
the mouse gene Dazla and the Drosophila gene boule is
autosomal and expressed only in the human male gonad. Hum Mol Genet 5:20052011[Abstract/Free Full Text]
-
Yen PH, Chai NN, Salido EC 1996 The human
autosomal gene DAZLA: testis specificity and a candidate for male
infertility. Hum Mol Genet 5:20132017[Abstract/Free Full Text]
-
Seboun E, Barbaux S, Bourgeron T, Nishi S, Agulnik A,
Egashira M, Nikkawa N, Bishop C, Fellous M, McElreavey K, Kasahara
M 1997 Gene sequence, localization, and evolutionary conservation
of DAZLA, a candidate male sterility gene. Genomics 41:227235[CrossRef][Medline]
-
Chai NN, Phillips A, Fernandez A, Yen PH 1997 A
putative human male infertility gene DAZLA: genomic structure and
methylation status. Mol Hum Reprod 3:705708[Abstract/Free Full Text]
-
Wong J, Blanco P, Affara NA 1999 An exon map of
the AZFc male infertility region of the human Y chromosome. Mamm Genome 10:5761[CrossRef][Medline]
-
Eberhart CG, Maines JZ, Wasserman SA 1996 Meiotic
cell cycle requirement for a fly homologue of human deleted in
azoospermia. Nature 381:783785[CrossRef][Medline]
-
Burgoyne PS 1996 Fruit(less) flies provide a
clue. Nature 381: 740741
-
Slee R, Grimes B, Speed RM, Taggart M, Maguire SM,
Ross A, McGill NI, Saunders PT, Cooke HJ 1999 A human DAZ
transgene confers partial rescue of the mouse Dazl null phenotype. Proc
Natl Acad Sci USA 96:80408045[Abstract/Free Full Text]
-
Mazeyrat S, Saut N, Sargent CA, Grimmond S, Longepied
G, Ehrmann IE, Ellis PS, Greenfield A, Affara NA, Mitchell MJ 1998 The mouse Y chromosome interval necessary for spermatogonial
proliferation is gene dense with syntenic homology to the human AZFa
region. Hum Mol Genet 7:17131724[Abstract/Free Full Text]
-
Sargent CA, Boucher CA, Kirsch S, Brown G, Weiss B,
Trundley A, Burgoyne P, Saut N, Durand C, Levy N, Terriou P, Hargreave
T, Cooke H, Mitchell M, Rappold GA, Affara NA 1999 The critical
region of overlap defining the AZFa male infertility interval of
proximal Yq contains three transcribed sequences. J Med Genet 36:670677[Abstract/Free Full Text]
-
Sun C, Skaletsky H, Birren B, Devon K, Tang Z, Silber
S, Oates R, Page DC 1999 An azoospermic man with a de
novo point mutation in the Y-chromosomal gene USP9Y. Nat Genet 23:429432[CrossRef][Medline]
-
Foresta C, Ferlin A, Moro E Deletion and
expression analysis of AZFa-genes on the human Y chromosome revealed a
major role for DBY in male infertility. Hum Mol Genet 9:11611169
-
Sutcliffe MJ, Darling SM, Burgoyne PS 1991 Spermatogenesis in XY, XYSxra and XOSxra mice: a quantitative analysis
of spermatogenesis throughout puberty. Mol Reprod Dev 30:8189[CrossRef][Medline]
-
Brown GM, Furlong RA, Sargent CA, Erickson RP,
Longepied G, Mitchell M, Jones MH, Hargreave TB, Cooke HJ, Affara
NA 1998 Characterisation of the coding sequence and fine mapping
of the human DFFRY gene and comparative expression analysis and mapping
to the Sxrb interval of the mouse Y chromosome of the Dffry gene. Hum
Mol Genet 7:97107[Abstract/Free Full Text]
-
Vogt MHJ, de Paus RA, Voogt PJ, Willemze R, Falkenburg
JHF 2000 DFFRY codes for a new human male-specific minor
transplantation antigen involved in bone marrow graft rejection. Blood 95:11001105[Abstract/Free Full Text]
-
Ferlin A, Moro E, Garolla A, Foresta C 1999 Human
male infertility and Y chromosome deletions: role of the AZF-candidate
genes DAZ, RBM and DFFRY. Hum Reprod 14:17101716[Abstract/Free Full Text]
-
Najmabadi H, Huang V, Yen P, Subbarao MN, Bhasin D,
Banaag L, Naseeruddin S, de Kretser DM, Baker HW, McLachlan RI,
Loveland KA, Bhasin S 1996 Substantial prevalence of
microdeletions of the Y-chromosome in infertile men with idiopathic
azoospermia and oligozoospermia detected using a sequence-tagged
site-based mapping strategy. J Clin Endocrinol Metab 81:13471352[Abstract]
-
Foresta C, Ferlin A, Garolla A, Rossato M, Barbaux S,
De Bortoli A 1997 Y-chromosome deletions in idiopathic severe
testiculopathies. J Clin Endocrinol Metab 82:10751080[Abstract/Free Full Text]
-
Foresta C, Ferlin A, Garolla A, Moro E, Pistorello M,
Barbaux S, Rossato M 1998 High frequency of well-defined
Y-chromosome deletions in idiopathic Sertoli cell-only syndrome. Hum
Reprod 13:302307
-
Linder P, Lasko PF, Ashburner M, Leroy P, Nielsen PJ,
Nishi K, Schnier J, Slonimski PP 1989 Birth of the D-E-A-D box
(letter). Nature 337:121122[CrossRef][Medline]
-
Chuang RY, Weaver PL, Liu Z, Chang TH 1997 Requirement of the DEAD box protein Ded1p for messenger RNA
translation. Science 275:14681471[Abstract/Free Full Text]
-
Foote S, Vollrath D, Hilton A, Page DC 1992 The
human Y chromosome: overlapping DNA clones spanning the euchromatic
region. Science 258:6066[Abstract/Free Full Text]
-
Kobayashi K, Mizuno K, Hida A, Komaki R, Tomita K,
Matsushita I, Namiki M, Iwamoto T, Tamura S, Minowada S, Nakahori Y,
Nakagome Y 1994 PCR analysis of the Y chromosome long arm in
azoospermic patients: evidence for a second locus required for
spermatogenesis. Hum Mol Genet 3:19651967[Abstract/Free Full Text]
-
Henegariu O, Hirschmann P, Kilian K, Kirsch S,
Lengauer C, Maiwald R, Mielke K, Vogt P 1994 Rapid screening of
the Y chromosome in idiopathic sterile men, diagnostic for deletions in
AZF, a genetic Y factor expressed during spermatogenesis. Andrologia 26:97106[Medline]
-
Kostiner DR, Turek PJ, Reijo RA 1998 Male
infertility: analysis of the markers and genes on the human Y
chromosome. Hum Reprod 13:30323038[Abstract/Free Full Text]
-
Pryor JL, Kent-First M, Muallem A, VanBergen AH,
Nolten WE, Meisner L, Roberts KP 1997 Microdeletions in the Y
chromosome of infertile men. N Engl J Med 336:534539[Abstract/Free Full Text]
-
Simoni M, Bakker E, Eurlings MC, Matthijs G, Moro E,
Muller CR, Vogt PH 1999 Laboratory guidelines for molecular
diagnosis of Y-chromosomal microdeletions. Int J Androl 22:292299[CrossRef][Medline]
-
Nagafuchi S, Namiki M, Nakahori Y, Kondoh N, Okuyama
A, Nakagome Y 1993 A minute deletion of Y chromosome in men with
azoospermia. J Urol 150:11551157[Medline]
-
Krausz C, Bussani-Mastellone C, Granchi S, McElreavey
K, Scarselli G, Forti G 1999 Screening for microdeletions of Y
chromosome genes in patients undergoing intracytoplasmic sperm
injection. Hum Reprod 14:17171721[Abstract/Free Full Text]
-
Reijo R, Alagappan RK, Patrizio P, Page DC 1996 Severe oligozoospermia resulting from deletions of azoospermia factor
gene on Y chromosome. Lancet 347:12901293[CrossRef][Medline]
-
Girardi SK, Mielnik A, Schlegel PN 1997 Submicroscopic deletions in the Y chromosome of infertile men. Hum
Reprod 12:16351641[Abstract/Free Full Text]
-
Kleiman SE, Yogev L, Gamzu R, Hauser R, Botchan A,
Lessing JB, Paz G, Yavetz H 1999 Genetic evaluation of infertile
men. Hum Reprod 14:3338[Abstract/Free Full Text]
-
Kremer JA, Tuerlings JH, Meuleman EJ, Schoute F,
Mariman E, Smeets DF, Hoefsloot LH, Braat DD, Merkus HM 1997 Microdeletions of the Y chromosome and intracytoplasmic sperm
injection: from gene to clinic. Hum Reprod 12:687691[Abstract/Free Full Text]
-
Stuppia L, Mastroprimiano G, Calabrese G, Peila R,
Tenaglia R, Palka G 1996 Microdeletions in interval 6 of the Y
chromosome detected by STS-PCR in 6 of 33 patients with idiopathic
oligo- or azoospermia. Cytogenet Cell Genet 72:155158[Medline]
-
Stuppia L, Gatta V, Mastroprimiano G, Pompetti F,
Calabrese G, Guanciali Franchi P, Morizio E, Mingarelli R, Nicolai M,
Tenaglia R, Improta L, Sforza V, Bisceglia S, Palka G 1997 Clustering of Y chromosome deletions in subinterval E of interval 6
supports the existence of an oligozoospermia critical region outside
the DAZ gene. J Med Genet 34:881883[Abstract/Free Full Text]
-
Krausz C, Quintana-Murci L, Barbaux S, Siffroi FP,
Rouba H, Delafontaine D, Souleyreau-Therville N, Arvis G, Antoine JM,
Erdei E, Taar JP, Tar A, Jeandidier E, Plessis G, Bourgeron T, Dadoune
JP, Fellous M, McElreavey K 1999 A high frequency of Y chromosome
deletions in males with noidiopathic infertility. J Clin
Endocrinol Metab 84:36063612[Abstract/Free Full Text]
-
Vereb M, Agulnik AI, Houston JT, Lipschultz LI, Lamb
DJ, Bishop CE 1997 Absence of DAZ gene mutations in cases of
non-obstructed azoospermia. Mol Hum Reprod 3:5559[Abstract/Free Full Text]
-
van der Ven K, Montag M, Peschka B, Leygraaf J,
Schwanitz G, Haidl G, Krebs D, van der Ven H 1997 Combined
cytogenetic and Y chromosome microdeletion screening in males
undergoing intracytoplasmic sperm injection. Mol Hum Reprod 3:699704[Abstract/Free Full Text]
-
Yoon HS, Lee JH, Seo JT, Kim HJ, Lee DR, Jeon JS, Cho
JH, Roh SI, The incidence of Y chromosome microdeletions and the
frequency of AZFa, b, c deletions in male infertility patients. Program
of the 53rd Annual Meeting of the American
Society for Reproductive Medicine, Cincinnati, OH, 1997 (Abstract O-067)
-
Liow SL, Ghadessy FJ, Ng SC, Yong EL 1998 Y
chromosome microdeletions, in azoospermic or near-azoospermic subjects,
are located in the AZFc (DAZ) subregion. Mol Hum Reprod 4:763768[Abstract/Free Full Text]
-
Simoni M, Gromoll J, Dworniczak B, Rolf C, Abshagen K,
Kamischke A, Carani C, Meschede D, Behre HM, Horst J, Nieschlag E 1997 Screening for deletions of the Y chromosome involving the DAZ
(deleted in azoospermia) gene in azoospermia and severe
oligozoospermia. Fertil Steril 67:542547[CrossRef][Medline]
-
Rucker GB, Mielnik A, King P, Goldstein M, Schlegel
PN 1998 Preoperative screening for genetic abnormalities in men
with nonobstructive azoospermia before testicular sperm extraction.
J Urol 160:20682071[CrossRef][Medline]
-
Mulhall JP, Reijo R, Alagappan R, Brown L, Page D,
Carson R, Oates RD 1997 Azoospermic men with deletion of the DAZ
gene cluster are capable of completing spermatogenesis: fertilization,
normal embryonic development and pregnancy occur when retrieved
testicular spermatozoa are used for intracytoplasmic sperm injection.
Hum Reprod 12:503508
-
Brandell RA, Mielnik A, Liotta D, Ye Z, Veeck LL,
Palermo GD, Schlegel PN 1998 AZFb deletions predict the absence of
spermatozoa with testicular sperm extraction: preliminary report of a
prognostic genetic test. Hum Reprod 13:28122815[Abstract/Free Full Text]
-
Silber SJ, Alagappan R, Brown LG, Page DC 1998 Y
chromosome deletions in azoospermic and severely oligozoospermic men
undergoing intracytoplasmic sperm injection after testicular sperm
extraction. Hum Reprod 13:33322227[Abstract/Free Full Text]
-
Grimaldi P, Scarponi C, Rossi P, March MR, Fabbri A,
Isidori A, Spera G, Krausz C, Geremia R 1998 Analysis of Yq
microdeletions in infertile males by PCR and DNA hybridization
techniques. Mol Hum Reprod 4:11161121[Abstract/Free Full Text]
-
Kim SW, Kim KD, Paick JS 1999 Microdeletions
within the azoospermia factor subregions of the Y chromosome in
patients with idiopathic azoospermia. Fertil Steril 72:349353[CrossRef][Medline]
-
Nakahori Y, Kuroki Y, Komaki R, Kondoh N, Namiki M,
Iwamoto T, Toda T, Kobayashi K 1996 The Y chromosome region
essential for spermatogenesis. Horm Res 46:2023
-
Bonhoff A, Fischer R, Baukloh V, Naether OG, Schulze
W, Hoppner W 1997 Frequency of Y-chromosome microdeletions
(Yq11.2223) in men with reduced sperm quality requesting assisted
reproduction. Adv Exp Med Biol 424:3135[Medline]
-
Vogt P, Chandley AC, Hargreave TB, Keil R, Ma K,
Sharkey A 1992 Microdeletions in interval 6 of the Y chromosome of
males with idiopathic sterility point to disruption of AZF, a human
spermatogenesis gene. Hum Genet 89:491496[Medline]
-
Kent-First MG, Kol S, Muallem A, Ofir R, Manor D,
Blazer S, First N, Itskovitz-Eldor J 1996 The incidence and
possible relevance of Y-linked microdeletions in babies born after
intracytoplasmic sperm injection and their infertile fathers. Mol Hum
Reprod 2:943950[Abstract/Free Full Text]
-
Hoefsloot LH, Tuerlings JH, Kremer JA, Meuleman
EJ 1997 PCR analysis of Y-chromosome deletions in subfertile men.
Lancet 349:1400
-
Int Veld PA, Halley DJ, van Hemel JO, Niermeijer MF,
Dohle G 1997 Genetic counselling before intracytoplasmic sperm
injection. Lancet 350:490[Medline]
-
Qureshi SJ, Ross AR, Ma K, Cooke HJ, Intyre MA,
Chandley AC, Hargreave TB 1996 Polymerase chain reaction screening
for Y chromosome microdeletions: a first step towards the diagnosis of
genetically-determined spermatogenic failure in men. Mol Hum Reprod 2:775779[Abstract/Free Full Text]
-
Silber SJ, Alagappan R, Brown L, Page DC 1997 Y
chromosomal deletions in azoospermic and oligozoospermic men undergoing
ICSI. Program of the 53rd Annual Meeting of the
American Society for Reproductive Medicine, Cincinnati, OH, 1997
(Abstract O-014)
-
Foresta C, Ferlin A, Bettella A, Rossato M, Varotto
A 1995 Diagnostic and clinical features in azoospermia. Clin
Endocrinol (Oxf) 43:537543[Medline]
-
Chang PL, Sauer MV, Brown S 1999 Y chromosome
microdeletion in a father and his four infertile sons. Hum Reprod 14:26892694[Abstract/Free Full Text]
-
Stuppia L, Calabrese G, Franchi PG, Mingarelli R, Gatta
V, Palka G, Dallapiccola B 1996 Widening of a Y-chromosome
interval-6 deletion transmitted from a father to his infertile son
accounts for an oligozoospermia critical region distal to the RBM1 and
DAZ genes. Am J Hum Genet 59:13931395[Medline]
-
Edwards RG, Bishop CE 1997 On the origin and
frequency of Y chromosome deletions responsible for severe male
infertility. Mol Hum Reprod 3:549554[Abstract/Free Full Text]
-
Tateno T, Sasagawa I, Ichiyanagi O, Ashida J, Nakada T,
Saito H, Hiroi M 1999 Microdeletion of the DAZ (deleted in
azoospermia) gene or the YRRM (Y chromosome ribonucleic acid
recognition motif) gene does not occur in patients with Klinefelters
syndrome with and without spermatogenesis. Fertil Steril 71:746749[CrossRef][Medline]
-
Foresta C, Moro E, Garolla A, Onisto M, Ferlin A 1999 Y chromosome microdeletions in cryptorchidism and idiopathic
infertility. J Clin Endocrinol Metab 84:36603665[Abstract/Free Full Text]
-
Moro E, Marin P, Rossi A, Garolla A, Ferlin
A 2000 Y chromosome microdeletions in infertile men with
varicocele. Mol Cell Endocrinol 161:6771[CrossRef][Medline]
-
Foresta C, Ferlin A, Moro E, Scandellari C 2000 Y
chromosome. Lancet 355:234235[Medline]
-
Simoni M, Kamischke A, Nieschlag E 1998 Current
status of the molecular diagnosis of Y-chromosomal microdeletions in
the work-up of male inefrtility. Initiative for international quality
control. Hum Reprod 13:17641768[Free Full Text]
-
Tesarik J, Mendoza C, Testard J 1995 Viable
embryos from injection of round spermatids into oocytes. N Engl
J Med 333:525[Free Full Text]
-
Tesarik J, Rolet F, Brami C, Sedbon E, Thorel J, Tibi
C, Thebault A 1996 Spermatid injection into human oocytes. II.
Clinical application in the treatment of infertility due to
non-obstructive azoospermia. Hum Reprod 11:780783[Abstract/Free Full Text]
-
Foresta C, Rossato M, Garolla A, Ferlin A 1996 Male infertility and ICSI: are there limits? Hum Reprod 11:23472348[Free Full Text]
-
Foresta C, Garolla A, Ferlin A, Galeazzi C, Rossato
M 1996 Use of intracytoplasmic sperm injection in severe male
factor infertility. Lancet 348:59
-
Page DC, Silber S, Brown LG 1999 Men with
infertility caused by AZFc deletion can produce sons by
intracytoplasmic sperm injection, but are likely to transmit the
deletion and infertility. Hum Reprod 14:17221726[Abstract/Free Full Text]
-
Jiang MC, Lien YR, Chen SU, Ko TM, Ho HN, Yang YS 1998 Transmission of de novo mutations of the deleted in
azoospermia genes from a severely oligozoospermic male to a son via
intracytoplasmic sperm injection. Fertil Steril 71:10291032
-
Kamischke A, Gromoll J, Simoni M, Behre HM, Nieschlag
E 1999 Transmission of a Y chromosomal deletion involving the
deleted in azoospermia (DAZ) and chromodomain (CDY1) genes from father
to son through intracytoplasmic sperm injection: case report. Hum
Reprod 14:23202322[Abstract/Free Full Text]
-
Rossato M, Ferlin A, Garolla A, Pistorello M, Foresta
C 1998 High fertilization rate in conventional in-vitro
fertilization utilizing spermatozoa from an oligozoospermic subject
presenting microdeletions of the Y chromosome long arm. Mol Hum Reprod 4:473476[Abstract/Free Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
S. G. Martinez-Garza, M. C. Gallegos-Rivas, M. Vargas-Maciel, J. M. Rubio-Rubio, M. E. de los Monteros-Rodriguez, C. Gonzalez-Ortega, P. Cancino-Villarreal, L. G. V. de Lara, and A. M. Gutierrez-Gutierrez
Genetic Screening in Infertile Mexican Men: Chromosomal Abnormalities, Y Chromosome Deletions, and Androgen Receptor CAG Repeat Length
J Androl,
November 1, 2008;
29(6):
654 - 660.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Foresta, D. Zuccarello, A. Garolla, and A. Ferlin
Role of Hormones, Genes, and Environment in Human Cryptorchidism
Endocr. Rev.,
August 1, 2008;
29(5):
560 - 580.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R.H. Martin
Cytogenetic determinants of male fertility
Hum. Reprod. Update,
June 4, 2008;
(2008)
dmn017v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Costa, R. Goncalves, C. Ferras, S. Fernandes, A. T. Fernandes, M. Sousa, and A. Barros
Identification of new breakpoints in AZFb and AZFc
Mol. Hum. Reprod.,
April 1, 2008;
14(4):
251 - 258.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.C. Lardone, D.A. Parodi, R. Valdevenito, M. Ebensperger, A. Piottante, M. Madariaga, R. Smith, R. Pommer, N. Zambrano, and A. Castro
Quantification of DDX3Y, RBMY1, DAZ and TSPY mRNAs in testes of patients with severe impairment of spermatogenesis
Mol. Hum. Reprod.,
October 1, 2007;
13(10):
705 - 712.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ferlin, E. Speltra, A. Garolla, R. Selice, D. Zuccarello, and C. Foresta
Y chromosome haplogroups and susceptibility to testicular cancer
Mol. Hum. Reprod.,
September 1, 2007;
13(9):
615 - 619.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Hadjkacem-Loukil, I. Ayadi, A. Bahloul, H. Ayadi, and L. Ammar-Keskes
Tag STS in the AZF Region Associated With Azoospermia in a Tunisian Population
J Androl,
September 1, 2007;
28(5):
652 - 658.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Bronson, S. K. Bronson, and L. D. Oula
Ability of Abnormally-Shaped Human Spermatozoa to Adhere to and Penetrate Zona-Free Hamster Eggs: Correlation With Sperm Morphology and Postincubation Motility
J Androl,
September 1, 2007;
28(5):
698 - 705.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Zhang, C. Lu, Z. Li, P. Xie, Y. Xia, X. Zhu, B. Wu, X. Cai, X. Wang, J. Qian, et al.
Partial deletions are associated with an increased risk of complete deletion in AZFc: a new insight into the role of partial AZFc deletions in male infertility
J. Med. Genet.,
July 1, 2007;
44(7):
437 - 444.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. L'Hote, C. Serres, P. Laissue, A. Oulmouden, C. Rogel-Gaillard, X. Montagutelli, and D. Vaiman
Centimorgan-Range One-Step Mapping of Fertility Traits Using Interspecific Recombinant Congenic Mice
Genetics,
July 1, 2007;
176(3):
1907 - 1921.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Bhasin
Approach to the Infertile Man
J. Clin. Endocrinol. Metab.,
June 1, 2007;
92(6):
1995 - 2004.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. S. Dhillon, M. Shahid, and S. A. Husain
Associations of MTHFR DNMT3b 4977 bp deletion in mtDNA and GSTM1 deletion, and aberrant CpG island hypermethylation of GSTM1 in non-obstructive infertility in Indian men
Mol. Hum. Reprod.,
April 1, 2007;
13(4):
213 - 222.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ferlin, B. Arredi, E. Speltra, C. Cazzadore, R. Selice, A. Garolla, A. Lenzi, and C. Foresta
Molecular and Clinical Characterization of Y Chromosome Microdeletions in Infertile Men: A 10-Year Experience in Italy
J. Clin. Endocrinol. Metab.,
March 1, 2007;
92(3):
762 - 770.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Arredi, A. Ferlin, E. Speltra, C. Bedin, D. Zuccarello, F. Ganz, E. Marchina, L. Stuppia, C. Krausz, and C. Foresta
Y-chromosome haplogroups and susceptibility to azoospermia factor c microdeletion in an Italian population
J. Med. Genet.,
March 1, 2007;
44(3):
205 - 208.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Kostova, C.H. Yeung, C.M. Luetjens, M. Brune, E. Nieschlag, and J. Gromoll
Association of three isoforms of the meiotic BOULE gene with spermatogenic failure in infertile men
Mol. Hum. Reprod.,
February 1, 2007;
13(2):
85 - 93.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. Yatsenko, A. Roy, R. Chen, L. Ma, L. J. Murthy, W. Yan, D. J. Lamb, and M. M. Matzuk
Non-invasive genetic diagnosis of male infertility using spermatozoal RNA: KLHL10mutations in oligozoospermic patients impair homodimerization
Hum. Mol. Genet.,
December 1, 2006;
15(23):
3411 - 3419.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-C. Lee, Y.-M. Jeong, S. H. Lee, K. Y. Cha, S.-H. Song, N. K. Kim, K. W. Lee, and S. Lee
Association study of four polymorphisms in three folate-related enzyme genes with non-obstructive male infertility
Hum. Reprod.,
December 1, 2006;
21(12):
3162 - 3170.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Hellani, S. Al-Hassan, A. Al-Duraihim, and S. Coskun
Y chromosome microdeletions: are they implicated in teratozoospermia?
Hum. Reprod.,
December 1, 2005;
20(12):
3505 - 3509.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Lynch, D.S. Cram, A. Reilly, M.K. O'Bryan, H.W.G. Baker, D.M. de Kretser, and R.I. McLachlan
The Y chromosome gr/gr subdeletion is associated with male infertility
Mol. Hum. Reprod.,
July 1, 2005;
11(7):
507 - 512.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ferlin, A. Garolla, A. Bettella, L. Bartoloni, C. Vinanzi, A. Roverato, and C. Foresta
Androgen receptor gene CAG and GGC repeat lengths in cryptorchidism
Eur. J. Endocrinol.,
March 1, 2005;
152(3):
419 - 425.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A Ferlin, A Tessari, F Ganz, E Marchina, S Barlati, A Garolla, B Engl, and C Foresta
Association of partial AZFc region deletions with spermatogenic impairment and male infertility
J. Med. Genet.,
March 1, 2005;
42(3):
209 - 213.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Arnedo, C. Nogues, M. Bosch, and C. Templado
Mitotic and meiotic behaviour of a naturally transmitted ring Y chromosome: reproductive risk evaluation
Hum. Reprod.,
February 1, 2005;
20(2):
462 - 468.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Clementini, C. Palka, I. Iezzi, L. Stuppia, P. Guanciali-Franchi, and G.M. Tiboni
Prevalence of chromosomal abnormalities in 2078 infertile couples referred for assisted reproductive techniques
Hum. Reprod.,
February 1, 2005;
20(2):
437 - 442.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Foresta, A. Garolla, L. Bartoloni, A. Bettella, and A. Ferlin
Genetic Abnormalities among Severely Oligospermic Men Who Are Candidates for Intracytoplasmic Sperm Injection
J. Clin. Endocrinol. Metab.,
January 1, 2005;
90(1):
152 - 156.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Hucklenbroich, J. Gromoll, M. Heinrich, C. Hohoff, E. Nieschlag, and M. Simoni
Partial deletions in the AZFc region of the Y chromosome occur in men with impaired as well as normal spermatogenesis
Hum. Reprod.,
January 1, 2005;
20(1):
191 - 197.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. de Llanos, J. L. Ballesca, C. Gazquez, E. Margarit, and R. Oliva
High frequency of gr/gr chromosome Y deletions in consecutive oligospermic ICSI candidates
Hum. Reprod.,
January 1, 2005;
20(1):
216 - 220.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Lespinasse, P. Hoffmann, A. Lauge, D. Stoppa-Lyonnet, F. Felmann, J.C. Pons, and G. Lesca
Chromosomal instability in two siblings with gonad deficiency: Case report
Hum. Reprod.,
January 1, 2005;
20(1):
158 - 162.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Tschanter, E. Kostova, C.M. Luetjens, T. G. Cooper, E. Nieschlag, and J. Gromoll
No association of the A260G and A386G DAZL single nucleotide polymorphisms with male infertility in a Caucasian population
Hum. Reprod.,
December 1, 2004;
19(12):
2771 - 2776.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Ferras, S. Fernandes, C.J. Marques, F. Carvalho, C. Alves, J. Silva, M. Sousa, and A. Barros
AZF and DAZ gene copy-specific deletion analysis in maturation arrest and Sertoli cell-only syndrome
Mol. Hum. Reprod.,
October 1, 2004;
10(10):
755 - 761.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Bartoloni, C. Cazzadore, A. Ferlin, A. Garolla, and C. Foresta
Lack of the T54A polymorphism of the DAZL gene in infertile Italian patients
Mol. Hum. Reprod.,
August 1, 2004;
10(8):
613 - 615.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ferlin, L. Bartoloni, G. Rizzo, A. Roverato, A. Garolla, and C. Foresta
Androgen receptor gene CAG and GGC repeat lengths in idiopathic male infertility
Mol. Hum. Reprod.,
June 1, 2004;
10(6):
417 - 421.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. T. Clark, K. Firozi, and M. J. Justice
Mutations in a Novel Locus on Mouse Chromosome 11 Resulting in Male Infertility Associated with Defects in Microtubule Assembly and Sperm Tail Function
Biol Reprod,
May 1, 2004;
70(5):
1317 - 1324.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Kuhnert, J. Gromoll, E. Kostova, P. Tschanter, C.M. Luetjens, M. Simoni, and E. Nieschlag
Case Report: Natural transmission of an AZFc Y-chromosomal microdeletion from father to his sons
Hum. Reprod.,
April 1, 2004;
19(4):
886 - 888.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Tessari, E. Salata, A. Ferlin, L. Bartoloni, M.L. Slongo, and C. Foresta
Characterization of HSFY, a novel AZFb gene on the Y chromosome with a possible role in human spermatogenesis
Mol. Hum. Reprod.,
April 1, 2004;
10(4):
253 - 258.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Lee, J. Hong, E. Kim, K. Kim, S. W. Kim, H. Krishnamurthy, S. S.W. Chung, D. J. Wolgemuth, and K. Rhee
Developmental stage-specific expression of Rbm suggests its involvement in early phases of spermatogenesis
Mol. Hum. Reprod.,
April 1, 2004;
10(4):
259 - 264.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G.H. Westerveld, J. Gianotten, N.J. Leschot, F. van derVeen, S. Repping, and M.P. Lombardi
Heterogeneous nuclear ribonucleoprotein G-T (HNRNP G-T) mutations in men with impaired spermatogenesis
Mol. Hum. Reprod.,
April 1, 2004;
10(4):
265 - 269.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ferlin, M. Simonato, L. Bartoloni, G. Rizzo, A. Bettella, T. Dottorini, B. Dallapiccola, and C. Foresta
The INSL3-LGR8/GREAT Ligand-Receptor Pair in Human Cryptorchidism
J. Clin. Endocrinol. Metab.,
September 1, 2003;
88(9):
4273 - 4279.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. J. Kurinczuk
Safety issues in assisted reproduction technology: From theory to reality--just what are the data telling us about ICSI offspring health and future fertility and should we be concerned?
Hum. Reprod.,
May 1, 2003;
18(5):
925 - 931.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A Ferlin, E Moro, A Rossi, B Dallapiccola, and C Foresta
The human Y chromosome's azoospermia factor b (AZFb) region: sequence, structure, and deletion analysis in infertile men
J. Med. Genet.,
January 1, 2003;
40(1):
18 - 24.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Frydelund-Larsen, C. Krausz, H. Leffers, A. M. Andersson, E. Carlsen, S. Bangsboell, K. Mcelreavey, N. E. Skakkebaek, and E. Rajpert-De Meyts
Inhibin B: A Marker for the Functional State of the Seminiferous Epithelium in Patients with Azoospermia Factor c Microdeletions
J. Clin. Endocrinol. Metab.,
December 1, 2002;
87(12):
5618 - 5624.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.M. Luetjens, J. Gromoll, M. Engelhardt, S. von Eckardstein, M. Bergmann, E. Nieschlag, and M. Simoni
Manifestation of Y-chromosomal deletions in the human testis: a morphometrical and immunohistochemical evaluation
Hum. Reprod.,
September 1, 2002;
17(9):
2258 - 2266.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Rolf, J. Gromoll, M. Simoni, and E. Nieschlag
Natural transmission of a partial AZFb deletion of the Y chromosome over three generations: Case report
Hum. Reprod.,
September 1, 2002;
17(9):
2267 - 2271.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. B. Zeyneloglu, V. Baltaci, H. E. Duran, E. Erdemli, and S. Batioglu
Achievement of pregnancy in globozoospermia with Y chromosome microdeletion after ICSI: Case report
Hum. Reprod.,
July 1, 2002;
17(7):
1833 - 1836.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Achermann, G. Ozisik, J. J. Meeks, and J. L. Jameson
Genetic Causes of Human Reproductive Disease
J. Clin. Endocrinol. Metab.,
June 1, 2002;
87(6):
2447 - 2454.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.G. Katz, B. Chu, R. McLachlan, N.I. Alexopoulos, D.M. de Kretser, and D.S. Cram
Genetic follow-up of male offspring born by ICSI, using a multiplex fluorescent PCR-based test for Yq deletions
Mol. Hum. Reprod.,
June 1, 2002;
8(6):
589 - 595.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I.D. Morris, S. Ilott, L. Dixon, and D.R. Brison
The spectrum of DNA damage in human sperm assessed by single cell gel electrophoresis (Comet assay) and its relationship to fertilization and embryo development
Hum. Reprod.,
April 1, 2002;
17(4):
990 - 998.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Foresta, E. Moro, and A. Ferlin
Prognostic value of Y deletion analysis: The role of current methods
Hum. Reprod.,
August 1, 2001;
16(8):
1543 - 1547.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Foresta, A. Bettella, E. Moro, A. Roverato, M. Merico, and A. Ferlin
Sertoli Cell Function in Infertile Patients with and without Microdeletions of the Azoospermia Factors on the Y Chromosome Long Arm
J. Clin. Endocrinol. Metab.,
June 1, 2001;
86(6):
2414 - 2419.
[Abstract]
[Full Text]
[PDF]
|
 |
|